Recently, zolbetuximab combined with chemotherapy, such as mFOLFOX6, which is a combination of the drugs leucovorin calcium, fluorouracil, and oxaliplatin or CAPOX, which is a combination of capecitabine and oxaliplatin demonstrated a survival benefit in patients with CLDN18.2-positive and HER-2-negative G/GEJ cancers [6,7]. The gene discussed is ERBB2; the disease is cancer.